Table 1.
Clinical trials with IC inhibitors in glioma (July, 2018).
| Target | Clin. Trial ID | Molecule | Disease | Phase | Patients | Status | Year S/E |
|---|---|---|---|---|---|---|---|
| CTLA-4 | NCT03460782 | Ipilimumab | Glioblastoma | I | ? | ? | 2018/? |
| PD-1 + CTLA-4 | NCT03430791 | Nivolumab + Ipilimumab | Glioblastoma | II | 60 | Not yet recruiting | 2018/2021 |
| NCT03233152 | Ipilimumab + Nivolumab | Glioblastoma | I | 6 | R | 2016/2019 | |
| NCT02017717 | Ipilimumab + Nivolumab + Bevacizumab | Glioblastoma | III | 626 | A-NR Data available (Ref. 59) | 2013/2018 | |
| NCT03367715 | Ipilimumab + Nivolumab | Glioblastoma MGMT Unmeth | II | 24 | R | 2018/2020 | |
| NCT02311920 | Ipilimumab + Nivolumab + TMZ | Glioblastoma Gliosarcoma | I | 32 | A-NR | 2015/2018 | |
| NCT03425292 | Ipilimumab + Nivolumab + TMZ | Glioblastoma | I | 45 | R | 2018/2020 | |
| NCT03422094 | Ipilimumab + Nivolumab + personalized vaccine (NeoVax) | Glioblastoma | I | 30 | Not yet recruiting | 2018/2023 | |
| CTLA-4 + PD-L1 | NCT02794883 | Tremelimumab + Durvalumab | Glioblastoma | II | 36 | R | 2016/2019 |
| PD-1 | NCT01952769 | Pidilizumab | DPIG | I/II | 50 | A-NR | 2014/2019 |
| NCT02359565 | Pembrolizumab | DPIG and other brain tumors | I | 110 | R | 2015/2020 | |
| NCT02529072 | Nivolumab + Dendritic cell vaccine | Glioblastoma | I | 7 | A-NR | 2015/2017 | |
| NCT03576612 | Nivolumab + immunostimulator | Glioblastoma | I | 36 | A-NR | 2018/2022 | |
| NCT03557359 | Nivolumab | IDHmut GB | II | 37 | A-NR | 2018/2021 | |
| NCT03347097 | PD-1 producing pluripotent killer cells | Glioblastoma | I | 40 | R | 2017/2018 | |
| NCT02311582 | Pembrolizumab + laser ablation | Glioma | I/II | 58 | R | 2015/2021 | |
| NCT02658981 | Nivolumab + anti-LAG-3 | Glioblastoma | I | 100 | R | 2016/2020 | |
| NCT02852655 | Pembrolizumab | Glioblastoma | NA | 35 | A-NR | 2016/2021 | |
| NCT02335918 | Nivolumab + Varilumab | Glioblastoma solid tumors | I/II | 175 | A-NR | 2015/2020 | |
| NCT02526017 | Cabiralizumab + Nivolumab | Glioblastoma solid tumors | I | 295 | A-NR | 2015/2019 | |
| NCT03058289 | INT230-6 (cytotoxic carrier, intratumor) + Nivolumab | Glioblastoma solid tumors | I/II | 60 | R | 2017/2020 | |
| NCT01860638 | Bevacizumab + Lomustine + Nivolumab + TMZ + Radiotherapy | Glioblastoma | III | 296 | C - No results available | 2013/2017 | |
| NCT03014804 | Dendridic cell vaccine + Nivolumab | Glioblastoma | II | 30 | To be started | 2018/2020 | |
| NCT03493932 | Nivolumab + Anti-LAG-3 | Glioblastoma | I | 15 | R | 2018/2021 | |
| NCT02798406 | Oncolytic Adenovirus (intratumor) + Nivolumab | Nervous System Tumors | II | 48 | R | 2016/2020 | |
| NCT02937844 | Chimeric T cells armed with PD-1 and CD28 to activate T cells and kill PD-L1+ tumor cells | Glioblastoma | I | 20 | R | 2016/2019 | |
| NCT03173950 | Nivolumab | Brain tumors not GB | II | 180 | R | 2017/2021 | |
| NCT03170141 | CAR-T cells | Glioblastoma | I | 20 | R by invitation | 2017/2020 | |
| NCT03491683 | Cemiplimab + immunomodulators INO-5401 and INO-9012 | Glioblastoma | I/II | 52 | R | 2018/2021 | |
| NCT02829931 | Nivolumab + radiotherapy | Glioblastoma | I | 26 | S by the Company | 2016/2020 | |
| NCT02550249 | Nivolumab | Glioblastoma | II | 29 | C - No results available | 2015/2017 | |
| NCT02648633 | Nivolumab + Valproic Acid | Glioblastoma | I | WT | 2016/2017 | ||
| NCT03452579 | Nivolumab + Bevacizumab | Glioblastoma | II | 90 | R | 2018/2018 | |
| NCT02667587 | Nivolumab + TMZ + radiotherapy | Glioblastoma | III | 693 | R | 2026/2023 | |
| NCT02617589 | Nivolumab + TMZ + radiotherapy | Glioblastoma | III | 550 | R | 2016/2019 | |
| NCT03311542 | Pembrolizumab | Glioblastoma Melanoma | ? | ? | ? | 2017/? | |
| NCT02313272 | Pembrolizumab + Bevacizumab + radiotherapy | Glioblastoma | I | 32 | A-NR Data Available (Ref: 62) | 2015/2019 | |
| NCT02054806 | Pembrolizumab | Glioblastoma and many solid tumors | I | 477 (26 GB) | A-NR Data Available (Ref: 61) | 2014/2018 | |
| PD1 + IDO | NCT03491683 | Epacadostat + Nivolumab | Glioblastoma | I/II | 52 | R | 2018/2021 |
| PD-L1 | NCT02968940 | Avelumab + radiotherapy | Glioblastoma IDHmut | II | 43 | R | 2017/2019 |
| NCT03291314 | Avelumab + Axitinib | Glioblastoma | II | 52 | R | 2017/2018 | |
| NCT02866747 | Durvalumab + radiotherapy | Glioblastoma | I/II | 62 | R | 2017/2020 | |
| NCT03341806 | Avelumab + lasertherapy | Glioblastoma | I | 30 | R | 2018/2020 | |
| NCT02336165 | Durvalumab + radiotherapy + Bevacizumab | Glioblastoma | II | 159 | A-NR Data Available (Ref:63) | 2015/2018 | |
| NCT03047473 | Avelumab | Glioblastoma | II | 30 | R | 2017/2019 | |
| NCT03174197 | Atezolizumab + TMZ | Glioblastoma | I/II | 60 | R | 2017/2021 | |
| NCT03158389 | Atezolizumab + targeted therapy with various molecules | Glioblastoma | I/II | 350 | R | 2018/2024 | |
| IDO | NCT02052648 | Indoximod + radiotherapy + TMZ + Bevacizumab | Glioblastoma | I/II | 160 | A-NR | 2014/2018 |
| NCT02502708 | Indoximod + TMZ + radiotherapy + other cytotoxic drugs | Pediatric brain tumors | I | 115 | R | 2015/2019 | |
| NCT02764151 | PF-06840003 | Brain tumors | I | 17 | A-NR | 2016/2018 |
Data taken from https://www.clinicaltrials.gov
R, Recruiting; C, Completed; A-NR, Active Not Recruiting; AC, Accrual completed; NI, Not Indicated; WT, Withdrawn; S, Suspended; Year S/E, Year Start/End.